Several new publications with CELLINKs technology

CELLINKs products has recently been featured in several new publications by customers and collaborators. The publications show the continues progress in the field of Bioprinting as well as how CELLINKs product range helps accelerate the research in the field.

One review focuses on developments in the field of bioprinting for musculoskeletal tissue engineering, along with discussion on the various approaches for bone, cartilage, and connective tissue fabrication. Title of review: 3D bioprinting for musculoskeletal applications.

In another study PDX Cells (Patient-derived Xeongrafts) were mixed with partially cross-linked hydrogel and printed with the INKREDIBLE 3D-Bioprinter. Title of study: Combination of CDODA-Me, a glycyrrhetinic acid derivative, and Erlotinib overcomes chemo-resistance in NSCLC PDX spheroids and 3D bio-printed cells, and New Frontiers in Biomaterials.

In New Frontiers in Biomaterials new advancements in the field of biomaterials for regenerative medicine are discussed. The article concludes that with recent advancements previously unattainable results within skin, nerve, muscle, and specialized tissue are now within reach.

“It’s exciting to see more publications where our technology has played a key part, and as time passes on we will see more and more publications during the next 12-months. Publications helps verifying the standard of our technology and is important for our long term-success and growth.” - Erik Gatenholm, CEO, CELLINK.

Read more:

http://www.oralmaxsurgery.theclinics.com/article/S1042-3699(16)30076-0/fulltext 

https://www.futuremedicine.com/doi/pdf/10.2217/3dp-2017-0004 

http://cancerres.aacrjournals.org/content/77/13_Supplement/2072.short 

For further information, please contact:

Erik Gatenholm, CEO                                     Gusten Danielsson, CFO

Phone: +46 73 267 00 00                             Phone: +46 70 991 86 04

E-mail: eg@cellink.com                                E-mail: gd@cellink.com

About CELLINK

CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. Mangold Fondkommission AB, tel: +46 (0) 8 5030 1550, is the Company's Certified Adviser.